The latest price target for FibroGen (NASDAQ:FGEN) was reported by HC Wainwright & Co. on September 24, 2025. The analyst firm set a price target for $43.00 expecting FGEN to rise to within 12 months (a possible 321.16% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for FibroGen (NASDAQ:FGEN) was provided by HC Wainwright & Co., and FibroGen reiterated their buy rating.

The last upgrade for FibroGen Inc happened on June 2, 2023 when Stifel raised their price target to N/A. Stifel previously had a hold for FibroGen Inc.

The last downgrade for FibroGen Inc happened on August 8, 2023 when B of A Securities changed their price target from $4 to $2 for FibroGen Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of FibroGen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for FibroGen was filed on September 24, 2025 so you should expect the next rating to be made available sometime around September 24, 2026.

While ratings are subjective and will change, the latest FibroGen (FGEN) rating was a reiterated with a price target of $43.00 to $43.00. The current price FibroGen (FGEN) is trading at is $10.21, which is out of the analyst’s predicted range.